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Introduction
Influenza is a major public health problem, causing 
an estimated 3 to 5 million cases of serious illness 
and 290,000 to 650,000 deaths due to respiratory 
infections per year worldwide [1]. There are four types 
of influenza viruses: A, B, C and D. Influenza A and B 
viruses cause seasonal epidemics of influenza disease; 
influenza type A viruses, unlike type B viruses, can 
also cause influenza pandemics, as their reservoir of 
infection is not only humans but also animal species. 
Influenza A viruses are further classified into subtypes 
according to the combinations of their two surface 
proteins, haemagglutinin (HA) and neuraminidase 
(NA), which are responsible for the infectious cycle of 
the influenza virus. Currently circulating in humans are 
subtypes A(H1N1) and A(H3N2) [2, 3]. A(H1N1) is 
also called A(H1N1)pdm09, as it caused a pandemic in 
2009 and subsequently replaced the seasonal influenza 
A(H1N1) virus which had circulated prior to 2009. 
Influenza B viruses are not classified into subtypes, 
but can be broken down into lineages. Currently 
circulating influenza type B viruses belong to either 
the B/Yamagata or the B/Victoria lineage. Influenza C 
virus is detected less frequently and usually causes mild 
infections; it does not therefore arouse public health 
concern. Influenza D viruses primarily affect cattle and 
are not known to infect or cause illness in people [1, 4]. 
At the global level, influenza surveillance is conducted 
by the Global Influenza Surveillance and Response 
System (GISRS), which is coordinated by the WHO [1]. 
The virological surveillance of influenza is an 
important means of determining the timing and spread 
of influenza viruses, tracking changes in circulating 
influenza viruses and informing seasonal influenza 
vaccine composition [5]. In Siena, the epidemiological 
surveillance of influenza has been carried out since the 
1980s [6, 7].
Only during the 2009 influenza pandemic did the need 
for more global data on severe influenza disease starkly 
emerge, promoting the World Health Organization to 
recommend conducting surveillance for severe acute 
respiratory infection in hospitalised patients; indeed, 
before 2011 a global surveillance case-definition 
of Severe Acute Respiratory Infections (SARI) did 
not exist. The proposed clinical case-definition of 
Background. Influenza is a major public health issue. Indeed, in 
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Severe Acute Respiratory Infections (SARI) at Le Scotte Univer-
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Methods. Oropharyngeal swabs were taken from SARI patients, 
who also completed a questionnaire recording their underlying 
diseases and vaccination status. Total RNA was extracted from 
each respiratory swab by means of the QIAamp Viral RNA Mini 
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Results. In this study we collected 68 swabs. The average age of 
subjects was 79.4 years (C.I.: 76.6-82.3) and 52.9% were female. 
The subjects had fever (89.7%), fatigue (77%), headache (47%), 
cough (75%), sore throat (70.5%), and breathlessness (63.2%). 
We found that 20% of the 68 subjects were positive (13% for A 
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rivalent). 
Conclusions. Our study is important in order to determine the 
timing and spread of influenza viruses and track changes in cir-
culating influenza viruses, so as to inform seasonal influenza vac-
cine composition. Seasonal vaccination is considered the most 
effective way to prevent influenza and its complications. 
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SARI in all age-groups therefore became “an acute 
respiratory illness with a history of fever or measured 
fever of ≥ 38°C and cough, with onset within the past 
10 days, requiring hospitalization”. To simplify the 
implementation process, the same criterion, i.e. “onset 
within the past 10 days”, was subsequently used in the 
case-definitions of both ILI (Influenza-like illness) and 
SARI [8-10]. 
Since the 2009/2010 pandemic season, Italy has been 
monitoring the evolution of severe and complicated 
forms of seasonal influenza. This surveillance aims to 
collect information on severe forms and deaths, in order 
to better understand the epidemiology of severe forms 
in the country, also in terms of possible risk factors and 
viral mutations during influenza epidemics [11].
In Italy, the virological and epidemiological 
surveillance of influenza is carried out by InfluNet 
[12]. This national surveillance system is based on 
a network of sentinel doctors made up of general 
practitioners and paediatricians, recruited by the 
Regional health authorities, who report cases of 
influenza-like syndrome (ILI) observed among their 
patients. Sentinel doctors and other doctors working 
in the territory and in hospitals also collaborate in the 
collection of biological samples for the identification 
of circulating viruses.
The collection and processing of disease reports is 
carried out by the Public Health Institute (ISS), which 
processes them at the national level and produces 
a weekly report that is published on the Ministry of 
Health website. The InFluNet network is integrated by 
FluNews, which collects the results of several influenza 
surveillance systems (Sismg, InfluWeb, InfluNet-Epi, 
InfluNet-Vir) [13]. Influenza severity measurements 
proposed by the WHO vary by influenza epidemic and 
cannot be deduced from ILI surveillance alone, thus 
emphasizing the potential use of and the necessity for 
prospective SARI surveillance, in order to assess the 
burden of seasonal influenza [14, 15].
The Italian Ministry of Health recommends that the 
monitoring of SARI be widely implemented in the 
intensive care units of local hospitals, and has requested 
their compliance [16]. Seasonal (or inter-pandemic) 
influenza surveillance generates information that can 
be used to plan appropriate measures of control and 
intervention (including vaccination), allocate health 
resources, and make recommendations for influenza 
case management [17].
All these surveillance systems are essential to 
the creation of a comprehensive representation 
of influenza from both the epidemiological and 
virological standpoints. Moreover, the reporting of 
SARI in a patient with chronic diseases ensures that 
the complications of influenza are not underestimated 
[18]. The consequences of influenza infection can 
be severe both for individuals and for the healthcare 
system. The severity of the infection depends on the 
type/subtype of the virus and the characteristics of the 
patient, including age (infants < 1 year and over 65 
years) and the presence of cardiovascular, respiratory, 
or immunodeficiency diseases. SARI caused by the 
influenza virus can result in hospitalisation [19-21]. 
Influenza vaccination is the most effective measure to 
prevent influenza disease. The WHO and EU countries, 
including Italy, recommend routine seasonal influenza 
vaccination for the elderly and individuals at increased 
risk of influenza complications, and have set a target 
of 95% influenza vaccine coverage for the elderly. In 
Italy, the three objectives of the seasonal vaccination 
campaign are: to reduce the individual’s risk of 
disease, hospitalization and death, to reduce the risk of 
transmission to subjects at risk of other complications 
or at risk of hospitalization, and to reduce the costs 
associated with the morbidity and mortality of the 
disease [22].
The 2017/2018 season saw the launch of the 
Development of Robust and Innovative Vaccine 
Effectiveness (DRIVE) project [23]. This project 
is a public–private partnership aimed at building 
the capacity for yearly estimation of brand-specific 
influenza vaccine effectiveness (IVE) in Europe. 
DRIVE is a five-year project funded by the IMI 
(Innovative Medicines Initiative) and our study is part 
of this project. It was initiated as a response to the 
guidelines on influenza vaccines issued by the EMA 
(European Medicines Agency), which advised vaccine 
manufacturers to work with public health institutes 
to set up a joint IVE study platform [23]. The data 
generated through DRIVE are expected to increase 
the understanding of influenza vaccine effectiveness, 
lead to enhanced monitoring of influenza vaccine 
performance by public health institutes and allow 
manufacturers to fulfil regulatory requirements [24].
In this study, we analysed the circulation of influenza 
viruses in the hospital setting in adult and elderly 
patients with SARI during the 2019/2020 season. 
Materials and Methods
Study Design
Oropharyngeal swabs were collected at the Unit of 
Emergency Medicine and Internal Medicine II of 
Le Scotte University Hospital in Siena, Italy, in the 
2019/2020 influenza season. In Italy, the influenza 
season lasts from 47/2019 to 17/2020 weeks. The study 
is an observational case-control study in which SARI 
cases confirmed for influenza and controls will be 
identified as such after the test has been performed cases 
confirmed for influenza and controls will be identified 
as such following laboratory testing laboratory test. 
The study is multicentre (see setting section), non-
commercial and will be conducted during the influenza 
season from 18 November 2019 and will end on 26 
April 2020. 
Sample collection was conducted in the context of the 
project DRIVE. The study was approved by the Ethics 
Committee of Area Vasta Sud Est Tuscany: approval 
Report n. 16344 of 16th December, 2019. Written 
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consent was obtain from all patients enrolled in the 
study.
The study population is made up of all non-
institutionalized subjects hospitalized for SARI, who 
do not present contraindications to flu vaccination.
Patients enrolled in the study presented symptoms (at 
least one systemic sign and symptom and one respiratory 
sign and symptom) and/or deterioration of their general 
condition at the time of hospital admission or within 
48 hours after admission. The symptoms considered 
were: fever, headache, myalgia, generalized malaise, 
cough, sore throat and breathing difficulties. During 
interviews, patients were asked about their vaccination 
status; each patient’s general practitioner was then 
asked to confirm the vaccination status and the type 
of vaccine (trivalent or quadrivalent). Patients were 
included if they had been vaccinated more than 14 days 
before the onset of SARI symptoms. The information 
was collected through a standardized questionnaire 
in which socio-demographic data and any underlying 
conditions were recorded. The swabs were collected by 
the ward doctor, stored at + 4°C and transported to the 
Molecular Epidemiology laboratory of the University 
of Siena and processed within 24 hours.
Laboratory Analysis
Total RNA was extracted from swabs by means of 
the QIAamp Viral RNA Mini kit (Qiagen, Hilden, 
Germany).
One-step real time RT-PCR was performed in a final 
volume of 25 µl with 0.8 µM forward and reverse 
primers, 0.2 µM probe and 5 µl of extracted RNA, in 
accordance with the manufacturer’s instructions for 
the use of the One-Step RT-PCR Kit (SuperScript 
III Platinum One-Step qRT-PCR Kit, Thermo Fisher 
Scientific, Waltham, MA, USA): Cycling conditions 
were 50°C for 30 minutes, 95°C for 2 minutes and 45 
cycles of 15 seconds at 95°C and 30 seconds at 55°C. 
Fluorescence was measured during the 55°C annealing/
extension step.
Statistical Analysis
The average ages of the study population and positive 
subjects were calculated. Frequencies, Standard 
Deviation (SD) and Confidence Interval (CI) were 
calculated. All statistical analyses were performed by 
means of GraphPad Prism 6 software and STATA.
Results
Sixty-eight oropharyngeal swabs were taken from 
patients with SARI. The first swab was collected on 
December 15, 2019, and the last swab was collected 
on March 15, 2020. Their average age was 79.4 years 
(SD:1.44; C.I.: 76.6-82.3). The median age was 82 and 
52.9% were female. 
The patients had fever (89.7%), fatigue (77%), 
headache (47%), cough (75%), sore throat (70.5%), and 
breathlessness (63.2%). Of the 68 patients, 25% had 
received a seasonal influenza vaccine (91.6% trivalent 
and 8.4% quadrivalent); 23.5% had not undergone anti-
pneumococcal vaccination, while 76.5% whether they 
had or not .We found that 20% of the 68 subjects were 
positive (13% for A H3N2 and 7% for A H1N1). The 
median age of the positive subjects was 79.5 years and 
57.1% were male. There were 12 positives among the 
unvaccinated, only 2 positives among the vaccinated 
were hospitalised. The positive subjects mostly had 
fever (100%), fatigue (71.4%), headache (28.6%), 
myalgia (35.7%), cough (78.6%), sore throat (57.1%), 
and breathlessness (50%) (Tab. I).
Positive subjects had a mean of 2.2 underlying 
conditions. The most common underlying diseases 
found in the positive subjects were: obesity (100%), 
cardiovascular diseases (50%), hypertension (50%), 
renal diseases (50%), lung diseases (42.8%), diabetes 
(35.7%), and cancer (35%). Other underlying conditions 
found in positive subjects were: haemopoietic organ 
diseases (14.3%), acquired immunosuppression 
(14.3%), liver disease/cirrhosis (7.1%), dementia 
(7.1%), stroke (7.1%), leukaemia or lymphomas 
(7.1%), and rheumatic diseases (7.1%) (Tab. II).
Among the positive subjects, 2 were smokers, 5 were 
ex-smokers, 4 had never smoked and 3 did not answer 
(Tab. III). 
Tab. I. Symptoms of positive subjects: number of subjects (N) and 
frequency (%).
Symptoms (N) % C.I.
Fever 14 100 0
Fatigue 10 71.4 0.01 - 0.55
Headache 4 28.6 0.44-0.98
Myalgia 6 42.9 0.27-0.86
Cough 11 78.6 -0.03-0.46
Sore throat 8 57.1 0.13-0.72
Breathlessness 7 50.0 0.20-0.79
Tab. II. The most frequent underlying condition in positive subjects
Underlying Conditions Freq. % C.I.
Cardiovascular diseases 7 50.0 0.20-0.79
Hypertension 7 50.0 0.20-0.79
Lung diseases 6 42.9 0.27-0.86
Diabetes 5 35.7 0.35-0.92
Renal diseases 7 50.0 0.20-0.79
Haemopoietic organ disease 2 14.3 0.64-1.06
Cancer 5 35.7 0.35-0.92
Liver disease/cirrhosis 1 7.1 0.77-1.08
Immunosuppression 2 14.3 0.64-1.06
Obesity 14 100 1
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Two of the positive subjects had been vaccinated with 
trivalent vaccine; in a 90-year-old woman, influenza 
virus A(H3N2) was identified, and in an 86-year-
old woman, influenza virus A (H1N1)pdm09 was 
identified. Both women had fever and cough. The 
86-year-old also had muscle pain and breathlessness. 
Table IV shows positive patients based on the type of 
influenza virus, symptoms, underlying conditions and 
vaccination status.
Discussion
In this study, we found that 20.5% of 68 subjects 
hospitalized in Siena, Tuscany with SARI symptoms 
were positive for influenza virus infection. Most of the 
infections were sustained by type A viruses, especially 
A (H3N2) viruses, which accounted for two-thirds of 
infections in our study. These values are in line with the 
trend reported by virological surveillance in Italy and 
in Europe [13,25-27]. In Europe, the first detections 
during the 2019-2020 season indicated co-circulation 
of influenza types A (71%) and B (29%) viruses in the 
WHO European Region. All four influenza subtypes 
and lineages circulated. Of the types A and B viruses 
detected, the A(H3N2) subtype and B/Victoria lineage 
were dominant in north-western Europe and Central 
Asia, respectively [26]. In Italy, from a virological 
point of view, the season was characterised by the 
predominant circulation of type A viruses (68%); 32% 
of viruses were of type B, and were isolated by InfluNet 
laboratories. Of the type A viruses, 54% belonged to 
the A(H3N2) subtype, 39% belonged to the A(H1N1)
pdm09 subtype, and 7% were not subtyped [25]. In 
particular, the most frequently identified subtype was 
A(H1N1)pdm09 at the sites in Finland, France and 
Spain (range 71.7% to 91.3%), and A(H3N2) at the 
sites in Austria, Italy and Romania[28]. 
In Italy, influenza vaccination coverage in the 
2019/2020 season was 54.6% in subjects aged over 
65 years and 16.8% in the general population [29]. In 
Tuscany instead, influenza vaccination coverage in the 
2019/2020 season was 54.6% in subjects aged over 65 
years[29]. In support of the importance of vaccination 
coverage, our study shows that of the hospitalised 
patients only two were vaccinated, all the others who 
tested positive had not been vaccinated.
The WHO recommended that quadrivalent vaccines 
for the 2019/2020 season should contain: an A/
Brisbane/02/2018 (H1N1)pdm09-like virus; an 
A/Kansas/14/2017 (H3N2)-like virus, and a B/
Colorado/06/2017-like virus (B/Victoria/2/87 
lineage) [30]. In the case of trivalent vaccines, 
the WHO recommended the insertion of the B/
Washington/02/2019-like virus strain (lineage B/
Victoria), in addition to the two types of A strain 
mentioned above.
During the 2019/2020 season, mismatch between 
the circulating A(H3N2) virus and the vaccine strain 
prompted the WHO to modify the composition of the 
vaccine for the 2020/2021 season [31, 32].
Following the first report of cases of acute respiratory 
syndrome in the Chinese municipality of Wuhan at the 
end of December 2019 [33], a pneumonia outbreak 
caused by human-to-human transmission of a new 
coronavirus rapidly spread, becoming a global pandemic 
[34]. In February 2020, the World Health Organization 
(WHO) named the novel coronavirus “SARS-CoV-2” 
and its associated spectrum of respiratory diseases 
“COVID-19” [35].
The signs and symptoms of SARS-CoV-2 infection 
overlap with those of many other viral respiratory tract 
infections, including those caused by influenza viruses. 
Beside “integrated COVID-19 surveillance”, which is 
specifically designed to track COVID-19 disease and 
to assess its burden, influenza surveillance can provide 
timely, high-quality data that can help to evaluate 
the SARS-CoV2 burden among populations with 
mild respiratory symptoms [36, 37]. The COVID-19 
outbreak impacted influenza surveillance; thus, the 
study period of the main analysis was truncated. Indeed, 
the pandemic and the subsequent lockdown measures 
curbed the already modest circulation of influenza 
and impacted data collection within DRIVE study 
sites [24]. Several DRIVE study sites implemented 
a different triage protocol in response to the SARS-
CoV-2 emergency, whereby all SARI patients arriving 
at hospitals were first tested for SARS-CoV-2; if the 
Tab. IV. Positive patients: number of subjects (N) and type of influ-
enza virus.
A/H1N1 (N.) A/H3N2 (N.)
Positive subjects 5 9
No Vaccination 4 8
Cardiovascular diseases 2 5
Hypertension 2 5
Lung diseases 1 6
Diabetes 1 4
Renal diseases 1 6
Haemopoietic organ disease 0 2
Cancer 3 2







Sore throat 4 4
Breathlessness 1 6





no answer 3 21.4
Total 14 100.0
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results were negative, tests were performed for other 
respiratory viruses, such as influenza. This new triage 
strategy was not expected to significantly reduce the 
number of influenza cases captured in the DRIVE 
dataset in 2019/2020, as very few cases of co-infection 
of influenza/SARS-CoV-2 were reported at the DRIVE 
sites that did test swabs for both viruses; this was due 
the minimal overlap between the influenza season and 
the emergence of the SARS-CoV-2 pandemic [24]. 
Moreover, during the pandemic, the implementation of 
strict public health measures (e.g. working from home, 
school closures, limiting social gatherings, increased 
hygiene measures, wearing masks etc.) to reduce 
SARS-CoV-2 transmission also reduced the circulation 
of other respiratory viruses. This was reflected by an 
all-time low level of influenza activity in the southern 
hemisphere and elsewhere in 2020 [38].
After consultation with the EMA and IMI in April 2020, 
the DRIVE consortium decided to take COVID-19 into 
account in its study documents (protocols, SAP, etc.) 
and operational procedures for the 2020/2021 season. 
Since then, DRIVE has closely tracked the evolution of 
the pandemic and has liaised with study sites in order 
to adapt rapidly to this ever-changing situation [24].
In the WHO European Region, unusually late and low-
level influenza activity was predicted for the 2020/21 
winter; these predictions were based on the low numbers 
of specimens testing positive for influenza virus that 
were detected in the summer months by sentinel and 
non-sentinel surveillance, despite substantial testing 
for influenza viruses during the COVID-19 pandemic 
[26,38]. Moreover, influenza surveillance can act as a 
global alert mechanism for the emergence of viruses 
with pandemic potential [1, 37].
The importance of influenza vaccination, especially for 
at-risk groups, remains a priority, as a higher influenza 
vaccination coverage rate in people aged 65 and over is 
associated with a reduced spread and a less severe clinical 
expression of COVID-19 [39]. The WHO recommends 
reconsidering the priority of risk groups for influenza 
vaccination during the COVID-19 pandemic for the 
following reasons: to ensure optimal influenza control 
among groups at high risk of severe COVID-19 disease 
and influenza; to reduce emergency room admissions 
and hospitalisations for influenza; and to ensure optimal 
management and use of potentially limited seasonal 
influenza vaccines worldwide [22, 39, 40].
Our study has some limitations. First, as the sample 
size was limited by the overall availability of swabs 
collected, it may not have been fully representative 
of the population. The hospital where the study was 
conducted is a 2nd level hospital with about 700 beds 
and the specific catchment area of the hospital has 
around 120,000 inhabitants as a reference for basic 
activities but only two departments participated in 
the study. In addition, many patients were not able 
to provide adequate answers regarding their medical 
history and vaccination status. In the future we will try 
to increase the sample by involving other units of the 
Le Scotte University Hospital in Siena.
Conclusions 
Overall, our data support the importance of seasonal 
influenza vaccination in subjects with chronic diseases, 
in order to reduce hospitalisations and mortality, 
and highlight the key role of epidemiological and 
virological surveillance as an essential tool for 
monitoring circulating viruses, identifying possible 
mismatches with seasonal vaccine strains, and 
providing information that can be used to improve the 
composition of influenza vaccines.
The virological surveillance of influenza is important, 
in order to determine the timing and spread of influenza 
viruses, to track changes in circulating influenza viruses 
and to inform seasonal influenza vaccine composition. 
Seasonal vaccination is considered the most effective 
way to prevent influenza and its complications. During 
the COVID-19 pandemic, influenza vaccination is an 
essential supplement for people at risk.
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